Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 101 - 150 av 169 resultater
Tid
Selskap
Tittel
Sektor
Kategori
04 Mar 2022
18:00 CET
ERYTECH PHARMA
Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2022
20103010 Biotechnology
Legal
08 Feb 2022
22:05 CET
ERYTECH PHARMA
ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases
20103010 Biotechnology
Products and services
08 Feb 2022
22:05 CET
ERYTECH PHARMA
ERYTECH élargit son portefeuille de brevets dans le traitement de maladies métaboliques rares
20103010 Biotechnology
Products and services
08 Feb 2022
18:00 CET
ERYTECH PHARMA
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2022
20103010 Biotechnology
Legal
08 Feb 2022
18:00 CET
ERYTECH PHARMA
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2022
20103010 Biotechnology
Legal
24 Jan 2022
07:30 CET
ERYTECH PHARMA
ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI
20103010 Biotechnology
Products and services
24 Jan 2022
07:30 CET
ERYTECH PHARMA
ERYTECH annonce la présentation des résultats de deux études cliniques évaluant eryaspase dans le traitement du cancer du pancréas lors du symposium ASCO-GI
20103010 Biotechnology
Products and services
10 Jan 2022
18:00 CET
ERYTECH PHARMA
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2021
20103010 Biotechnology
Legal
10 Jan 2022
18:00 CET
ERYTECH PHARMA
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2021
20103010 Biotechnology
Legal
03 Jan 2022
22:05 CET
ERYTECH PHARMA
ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
20103010 Biotechnology
Meetings / events
03 Jan 2022
22:05 CET
ERYTECH PHARMA
ERYTECH annonce sa participation en janvier à des conférences investisseurs virtuelles
20103010 Biotechnology
Meetings / events
14 Dec 2021
07:30 CET
ERYTECH PHARMA
ERYTECH annonce la levée de 7,85 millions de dollars dans le cadre d’une Registered Offering
20103010 Biotechnology
Other financial transaction
14 Dec 2021
07:30 CET
ERYTECH PHARMA
ERYTECH Announces $7.85 Million Registered Direct Offering
20103010 Biotechnology
Other financial transaction
13 Dec 2021
22:05 CET
ERYTECH PHARMA
ERYTECH annonce la présentation des résultats du programme d’accès élargi dans la LAL lors du congrès annuel de l’ASH 2021 et l’acceptation de deux abstracts à l’ASCO-GI
20103010 Biotechnology
Meetings / events
13 Dec 2021
22:05 CET
ERYTECH PHARMA
ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI
20103010 Biotechnology
Meetings / events
10 Dec 2021
18:00 CET
ERYTECH PHARMA
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 novembre 2021
20103010 Biotechnology
Legal
10 Dec 2021
18:00 CET
ERYTECH PHARMA
Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2021
20103010 Biotechnology
Legal
29 Nov 2021
22:05 CET
ERYTECH PHARMA
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
20103010 Biotechnology
New
29 Nov 2021
22:05 CET
ERYTECH PHARMA
ERYTECH obtient un brevet aux Etats-Unis pour l’utilisation de la méthioninase suivie de l’asparaginase dans le traitement des tumeurs solides
20103010 Biotechnology
New
15 Nov 2021
22:05 CET
ERYTECH PHARMA
ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
20103010 Biotechnology
Sales
15 Nov 2021
22:05 CET
ERYTECH PHARMA
ERYTECH fait le point sur ses activités et publie ses résultats du troisième trimestre 2021
20103010 Biotechnology
Sales
15 Nov 2021
07:30 CET
ERYTECH PHARMA
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
20103010 Biotechnology
New
15 Nov 2021
07:30 CET
ERYTECH PHARMA
ERYTECH annonce la présentation d’un poster lors du congrès annuel 2021 de l'American Society of Hematology
20103010 Biotechnology
New
10 Nov 2021
07:30 CET
ERYTECH PHARMA
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal
20103010 Biotechnology
New
10 Nov 2021
07:30 CET
ERYTECH PHARMA
ERYTECH annonce la publication d'un article sur la caractérisation des globules rouges dans un journal à facteur d'impact élevé
20103010 Biotechnology
New
09 Nov 2021
08:00 CET
ERYTECH PHARMA
ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference
20103010 Biotechnology
Meetings / events
09 Nov 2021
08:00 CET
ERYTECH PHARMA
ERYTECH présentera à l’occasion de la 12ème Conférence Jefferies Global London Healthcare
20103010 Biotechnology
Meetings / events
05 Nov 2021
18:21 CET
ERYTECH PHARMA
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 octobre 2021
20103010 Biotechnology
Legal
05 Nov 2021
18:21 CET
ERYTECH PHARMA
Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021
20103010 Biotechnology
Legal
25 Oct 2021
07:00 CEST
ERYTECH PHARMA
ERYTECH annonce les résultats de l’étude de phase 3 TRYbeCA-1 évaluant eryaspase comme traitement de seconde ligne chez des patients atteints d’un cancer avancé du pancréas
20103010 Biotechnology
New
25 Oct 2021
07:00 CEST
ERYTECH PHARMA
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer
20103010 Biotechnology
New
07 Oct 2021
18:00 CEST
ERYTECH PHARMA
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 Septembre 2021
20103010 Biotechnology
Other subject
07 Oct 2021
18:00 CEST
ERYTECH PHARMA
Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2021.
20103010 Biotechnology
Other subject
04 Oct 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
20103010 Biotechnology
Products and services
04 Oct 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH annonce la détermination de la Dose Maximale Tolérée dans le cadre de l’essai de Phase 1 mené par un investigateur avec eryaspase dans le traitement en première ligne du cancer du pancréas
20103010 Biotechnology
Products and services
28 Sep 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech
20103010 Biotechnology
Other subject
28 Sep 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH participera à la conférence HealthTech Innovation Days (HTID) organisée par France Biotech
20103010 Biotechnology
Other subject
22 Sep 2021
18:30 CEST
ERYTECH PHARMA
ERYTECH Announces the Availability of its Half-Year Financial Report 2021
20103010 Biotechnology
Other subject
22 Sep 2021
18:30 CEST
ERYTECH PHARMA
ERYTECH annonce la mise à disposition de son rapport financier semestriel 2021
20103010 Biotechnology
Other subject
20 Sep 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
20103010 Biotechnology
Income
20 Sep 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH fait le point sur ses activités et publie ses résultats semestriels 2021
20103010 Biotechnology
Income
15 Sep 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update
20103010 Biotechnology
Income
15 Sep 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH tiendra un webcast le 21 septembre 2021 à l’occasion de ses résultats semestriels 2021
20103010 Biotechnology
Income
06 Sep 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH tiendra une présentation à la H.C. Wainwright 23rd Annual Global Investment Conference
20103010 Biotechnology
Meetings / events
06 Sep 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
20103010 Biotechnology
Meetings / events
03 Sep 2021
18:00 CEST
ERYTECH PHARMA
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 août 2021
20103010 Biotechnology
Legal
03 Sep 2021
18:00 CEST
ERYTECH PHARMA
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2021
20103010 Biotechnology
Legal
30 Aug 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH annonce sa participation à la Citi 16th Annual BioPharma Conference
20103010 Biotechnology
Meetings / events
30 Aug 2021
22:05 CEST
ERYTECH PHARMA
ERYTECH to Participate in the Citi 16th Annual BioPharma Conference
20103010 Biotechnology
Meetings / events
24 Aug 2021
22:30 CEST
ERYTECH PHARMA
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer
20103010 Biotechnology
Meetings / events
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva